At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
H-1337 Placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating H-1337 Placebo, H-1337 [1], and 2 other interventions for Glaucoma, Open-Angle. Completed, enrolled 87 participants across 1 site.
Detailed Summary
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with elevated intraocular pressure (IOP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMar 2018
Primary CompletionAug 2018
TodayJul 2026
First PostedMar 2, 2018
Enrollment StartMar 15, 2018
Primary CompletionAug 15, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.3 years ago
Interventions
H-1337 Placebodrug
H-1337 Placebo Vehicle
H-1337 [1]drug
H-1337 Ophthalmic Solution Concentration 1
H-1337 [2]drug
H-1337 Ophthalmic Solution Concentration 2
H-1337 [3]drug
H-1337 Ophthalmic Solution Concentration 3